Literature DB >> 17472721

B-lymphocyte depletion ameliorates Sjögren's syndrome in Id3 knockout mice.

Ikuko Hayakawa1, Thomas F Tedder, Yuan Zhuang.   

Abstract

Sjögren's syndrome is an autoimmune disease in which immune cells chronically attack the lachrymal and salivary glands. The Id3 knockout mouse is a newly established animal model for primary Sjögren's syndrome. To address the role of B cells in Sjögren's syndrome and autoimmune disease, we studied the effect of CD20 monoclonal antibody treatment on the disease in Id3 knockout mice. Antibody treatment at 2-month intervals led to efficient and sustained B-cell depletion in Id3 knockout mice. A significant improvement of histopathology was observed accompanied by the recovery of saliva secretory function after CD20 antibody treatment. We further show that serum immunoglobulin G3, which is abnormally high in untreated Id3 knockout mice, was reduced after CD20 antibody treatment. This study establishes a new animal model for immunotherapy of Sjögren's symptoms and suggests a possible link between immunoglobulin G3 and disease pathology in Id3 knockout mice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17472721      PMCID: PMC2265983          DOI: 10.1111/j.1365-2567.2007.02614.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  22 in total

1.  Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome.

Authors:  M Voulgarelis; U G Dafni; D A Isenberg; H M Moutsopoulos
Journal:  Arthritis Rheum       Date:  1999-08

2.  Clinical associations of autoantibodies to human muscarinic acetylcholine receptor 3(213-228) in primary Sjogren's syndrome.

Authors:  L Kovács; I Marczinovits; A György; G K Tóth; L Dorgai; J Pál; J Molnár; G Pokorny
Journal:  Rheumatology (Oxford)       Date:  2005-05-11       Impact factor: 7.580

Review 3.  Update on rituximab.

Authors:  R Eisenberg
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

Review 4.  CD20: a regulator of cell-cycle progression of B lymphocytes.

Authors:  T F Tedder; P Engel
Journal:  Immunol Today       Date:  1994-09

Review 5.  Current issues in the diagnosis and treatment of Sjögren's syndrome.

Authors:  R I Fox; J Tornwall; P Michelson
Journal:  Curr Opin Rheumatol       Date:  1999-09       Impact factor: 5.006

6.  Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.

Authors:  J Pijpe; G W van Imhoff; F K L Spijkervet; J L N Roodenburg; G J Wolbink; K Mansour; A Vissink; C G M Kallenberg; H Bootsma
Journal:  Arthritis Rheum       Date:  2005-09

7.  The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice.

Authors:  Yasuhito Hamaguchi; Junji Uchida; Derek W Cain; Guglielmo M Venturi; Jonathan C Poe; Karen M Haas; Thomas F Tedder
Journal:  J Immunol       Date:  2005-04-01       Impact factor: 5.422

Review 8.  Cooperative binding by mouse IgG3 antibodies: implications for functional affinity, effector function, and isotype restriction.

Authors:  N S Greenspan; L J Cooper
Journal:  Springer Semin Immunopathol       Date:  1993

Review 9.  The risk of lymphoma development in autoimmune diseases: a meta-analysis.

Authors:  Elias Zintzaras; Michael Voulgarelis; Haralampos M Moutsopoulos
Journal:  Arch Intern Med       Date:  2005-11-14

Review 10.  Sjögren's syndrome.

Authors:  Robert I Fox
Journal:  Lancet       Date:  2005 Jul 23-29       Impact factor: 79.321

View more
  35 in total

1.  Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus.

Authors:  Kai W Bekar; Teresa Owen; Robert Dunn; Travis Ichikawa; Wensheng Wang; Roger Wang; Jennifer Barnard; Sean Brady; Sarah Nevarez; Bruce I Goldman; Marilyn Kehry; Jennifer H Anolik
Journal:  Arthritis Rheum       Date:  2010-08

2.  Protective Role for B-1b B Cells and IgM in Obesity-Associated Inflammation, Glucose Intolerance, and Insulin Resistance.

Authors:  Daniel B Harmon; Prasad Srikakulapu; Jennifer L Kaplan; Stephanie N Oldham; Chantel McSkimming; James C Garmey; Heather M Perry; Jennifer L Kirby; Thomas A Prohaska; Ayelet Gonen; Peter Hallowell; Bruce Schirmer; Sotirios Tsimikas; Angela M Taylor; Joseph L Witztum; Coleen A McNamara
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-02-11       Impact factor: 8.311

3.  B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice.

Authors:  Yuki Moritoki; Zhe-Xiong Lian; Keith Lindor; Joseph Tuscano; Koichi Tsuneyama; Weici Zhang; Yoshiyuki Ueno; Robert Dunn; Marilyn Kehry; Ross L Coppel; Ian R Mackay; M Eric Gershwin
Journal:  Hepatology       Date:  2009-12       Impact factor: 17.425

4.  Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression.

Authors:  Takashi Matsushita; Koichi Yanaba; Jean-David Bouaziz; Manabu Fujimoto; Thomas F Tedder
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

5.  Transient depletion of CD4+ CD25+ regulatory T cells results in multiple autoimmune diseases in wild-type and B-cell-deficient NOD mice.

Authors:  Jason S Ellis; Xiaoxiao Wan; Helen Braley-Mullen
Journal:  Immunology       Date:  2013-06       Impact factor: 7.397

6.  Regulatory T cells in B-cell-deficient and wild-type mice differ functionally and in expression of cell surface markers.

Authors:  Jason S Ellis; Helen Braley-Mullen
Journal:  Immunology       Date:  2015-04       Impact factor: 7.397

7.  B-cell aortic homing and atheroprotection depend on Id3.

Authors:  Amanda C Doran; Michael J Lipinski; Stephanie N Oldham; James C Garmey; Kirsti A Campbell; Marcus D Skaflen; Alexis Cutchins; Daniel J Lee; David K Glover; Kimberly A Kelly; Elena V Galkina; Klaus Ley; Joseph L Witztum; Sotirios Tsimikas; Timothy P Bender; Coleen A McNamara
Journal:  Circ Res       Date:  2011-10-27       Impact factor: 17.367

Review 8.  B-lymphocyte effector functions in health and disease.

Authors:  David J DiLillo; Mayuka Horikawa; Thomas F Tedder
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

9.  B cell-targeted therapy with anti-CD20 monoclonal antibody in a mouse model of Graves' hyperthyroidism.

Authors:  I Ueki; N Abiru; M Kobayashi; M Nakahara; T Ichikawa; K Eguchi; Y Nagayama
Journal:  Clin Exp Immunol       Date:  2011-01-14       Impact factor: 4.330

Review 10.  Genes and Sjögren's syndrome.

Authors:  Beth L Cobb; Christopher J Lessard; John B Harley; Kathy L Moser
Journal:  Rheum Dis Clin North Am       Date:  2008-11       Impact factor: 2.670

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.